Get the Stockscreener App
468.13
0.77%
3.57
After Hours:
486.85
18.72
+4.00%
Vertex Pharmaceuticals Inc stock is traded at $468.13, with a volume of 717.72K.
It is up +0.77% in the last 24 hours and down -0.47% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$464.56
Open:
$463.6
24h Volume:
717.72K
Relative Volume:
0.66
Market Cap:
$120.56B
Revenue:
$10.63B
Net Income/Loss:
$-479.80M
P/E Ratio:
35.12
EPS:
13.33
Net Cash Flow:
$-1.35B
1W Performance:
+3.81%
1M Performance:
-0.47%
6M Performance:
+6.12%
1Y Performance:
+33.37%
1-Day Range:
$462.33
$470.93
1-Week Range:
$455.82
$470.93
52-Week Range:
$347.51
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Sickle Cell Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer - The Globe and Mail
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Reduced by Martingale Asset Management L P - MarketBeat
Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock? - Nasdaq
Fiduciary Trust Co Has $5.59 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Grows Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Is Wall Street Bullish Or Bearish On Vertex Pharmaceuticals Stock? - Barchart
Townsquare Capital LLC Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank - MarketBeat
CreativeOne Wealth LLC Buys 3,242 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Trimmed by Fisher Asset Management LLC - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
MetLife Investment Management LLC Sells 1,828 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (FRA:VX1) 3-Year Dividend Growth Rat - GuruFocus.com
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
VRTX (Vertex Pharmaceuticals) Cyclically Adjusted PS Ratio : 20.05 (As of Nov. 26, 2024) - GuruFocus.com
VRTX (Vertex Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 26, 2024) - GuruFocus.com
VRTX (Vertex Pharmaceuticals) Inventory-to-Revenue : 0.36 (As of Sep. 2024) - GuruFocus.com
VRTX (Vertex Pharmaceuticals) Total Assets : $22,240 Mil (As of Sep. 2024) - GuruFocus.com
Fmr LLC Decreases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Dai ichi Life Insurance Company Ltd Has $12.14 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Bank of Montreal Can Has $257.93 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
The Manufacturers Life Insurance Company Sells 11,350 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
JPMorgan's 2025 Biotech Outlook: Vertex (VRTX) Leads the Pack - GuruFocus.com
Vertex leads J.P. Morgan's top biotech picks list for 2025 (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharma: Why I Am Buying This Dip (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Eagle Asset Management Inc. - MarketBeat
Loomis Sayles & Co. L P Has $1.43 Billion Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) shareholders are still up 137% over 3 years despite pulling back 3.4% in the past week - Yahoo Finance
Daiwa Securities Group Inc. Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? - The Motley Fool
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
VRTX (Vertex Pharmaceuticals) Cash Flow from Operations : $-843 Mil (TTM As of Sep. 2024) - GuruFocus.com
Pacer Advisors Inc. Sells 5,885 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
VRTX (Vertex Pharmaceuticals) Cash Flow from Investing : $-3,835 Mil (TTM As of Sep. 2024) - GuruFocus.com
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Icon Wealth Advisors LLC - MarketBeat
Edgewood Management LLC Has $719.19 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
What is Zacks Research's Estimate for VRTX FY2024 Earnings? - MarketBeat
Charles Schwab Investment Management Inc. Purchases 20,361 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Intech Investment Management LLC Has $8.24 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock - Insider Monkey
Got $500? 1 Biotech Stock to Buy and Hold Forever - Yahoo! Voices
MAI Capital Management Reduces Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
BofA flags Vertex Pharma stock at risk of double top breakdown - Investing.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
January 2025 Options Now Available For Vertex Pharmaceuticals (VRTX) - Nasdaq
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Citizens Financial Group Inc. RI - MarketBeat
Massachusetts Financial Services Co. MA Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):